Celsion Corporation Announces Stock Consolidation
26 mai 2017 16h05 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., May 26, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, announced today that it is effecting a 1 for 14 reverse stock split of...
Celsion Corporation Reports First Quarter 2017 Financial Results and Provides Business Update
12 mai 2017 08h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., May 12, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2017...
Celsion Corporation to Hold First Quarter 2017 Financial Results Conference Call on Friday, May 12, 2017
05 mai 2017 08h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., May 05, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
Celsion Updates Clinical Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients
04 mai 2017 08h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., May 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced updated additional clinical and translational research data from its Phase Ib dose...
Celsion Announces Presentation of OVATION Study Findings at the Upcoming ASCO 2017 Annual Meeting
20 avr. 2017 08h30 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., April 20, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided an update on its OVATION Study, a Phase Ib dose...
Celsion Corporation Reports Preclinical Results of ThermoDox® for the Treatment of Bladder Cancer Published in the International Journal of Hyperthermia
13 avr. 2017 08h30 HE
|
Celsion Corporation
Higher Concentrations of Doxorubicin Accumulation and Distribution within the Bladder Wall Were Achieved with ThermoDox® Combined with Mild Local Hyperthermia Compared to Free Doxorubicin Alone The...
Celsion Corporation Reports Year End 2016 Financial Results and Provides Business Update
16 mars 2017 09h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the year ended December 31,...
Celsion Corporation to Hold Year-End 2016 Financial Results Conference Call on Thursday, March 16, 2017
09 mars 2017 09h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., March 09, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss year-end 2016 financial results and...
Celsion Presents Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium
27 févr. 2017 08h30 HE
|
Celsion Corporation
OVATION Study Fully Enrolled, Final Patient Enrolled in the Fourth Cohort Complete Clinical and Translational Research Data to be Announced During the Second Quarter LAWRENCEVILLE, N.J., Feb. 27,...
Celsion Corporation Announces $5.0 Million Public Offering
15 févr. 2017 07h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the “Company”) (NASDAQ:CLSN) today announced the pricing of a public offering with expected total gross proceeds of...